Indian Journal of Medical and Paediatric Oncology, Table of Contents CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(04): 566-569DOI: 10.4103/ijmpo.ijmpo_276_19 Report on International Publication Interim-Response-Adapted Therapy in Advanced Hodgkin’s Lymphoma: Current Status Prasanth Ganesan Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India › Author Affiliations Recommend Article Abstract Full Text References References 1 Ganesan P, Rajendranath R, Kannan K, Radhakrishnan V, Ganesan TS, Udupa K. et al. Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin’s lymphoma. Ann Oncol 2015; 26: 1170-4 2 Ganesan P, Sagar T, Radhakrishnan V, Dhanushkodi M. Response-adapted therapy in Hodgkin’s lymphoma: Long-term follow up of a phase II clinical trial. Clin Lymphoma Myeloma Leuk 2018; 18: S231 3 Ganesan P, Kumar L, Raina V, Sharma A, Bakhshi S, Sreenivas V. et al. Hodgkin’s lymphoma—long-term outcome: An experience from a tertiary care cancer center in North India. Ann Hematol 2011; 90: 1153-60 4 Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 2003; 348: 2386-95 5 Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M. et al. Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-52 6 Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F. et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011; 152: 551-60 7 Gallamini A, Fiore F, Sorasio R, Meignan M. Interim positron emission tomography scan in Hodgkin lymphoma: Definitions, interpretation rules, and clinical validation. Leuk Lymphoma 2009; 50: 1761-4 8 Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma 2009; 50: 1257-60 9 Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M. et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest oncology group S0816. J Clin Oncol 2016; 34: 2020-7 10 Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M. et al. Five-year follow-up of SWOG S0816: Limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood 2019; 134: 1238-46 11 Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A. et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 2016; 374: 2419-29 12 Rotman J, Fossa A, Federico M. Response-adjusted therapy for advanced Hodgkin lymphoma (RATHL) trial: Longer follow up confirms efficacy of de-escalation after a negative interim pet scan (CRUK/07/033). Hematol Oncol 2017; 35: 65-7 13 Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mulé A. et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: Long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol 2018; 36: 454-62 14 Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA. et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2018; 390: 2790-802 15 Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A. et al. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: Final results of the phase II part of the HD0801 study. J Clin Oncol 2016; 34: 1376-85 16 Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A. et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): A randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 2019; 20: 202-15 17 Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M. et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 2014; 99: 1107-13 18 Agostinelli C, Gallamini A, Stracqualursi L, Agati P, Tripodo C, Fuligni F. et al. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin’s lymphoma: A retrospective, European, multicentre cohort study. Lancet Haematol 2016; 3: e467-e479 19 Ganesan P, Dhanushkodi M, Ganesan TS, Radhakrishnan V, Kannan K, Sundersingh S. et al. Prognostic utility of the IPS 3 score for predicting outcomes in advanced Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2019; 19: 116-22 20 Seshachalam A, Karpurmath SV, Rathnam K, Raman SG, Janarthinakani M, Prasad K. et al. Does interim PET scan after 2 cycles of ABVD predict outcome in Hodgkin lymphoma? Real-world evidence. J Glob Oncol 2019; 5: 1-3
